A carregar...
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
BACKGROUND: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2006
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1361775/ https://ncbi.nlm.nih.gov/pubmed/16398939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-5 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|